Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality

Journal of the American College of Cardiology

Volumn 68, Issue 3, 2016, Pages 252-260

  Besseling, Joost ^a   Hovingh, G Kees ^a   Huijgen, Roeland ^a   Kastelein, John J P ^a   Hutten, Barbara A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

intensity; inverse probability of treatment weighting; lipid lowering

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG EXPOSURE; DUTCHMAN; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RETROSPECTIVE STUDY; RISK REDUCTION; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; EPIDEMIOLOGY; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ADULT; ATORVASTATIN CALCIUM; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; NETHERLANDS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SIMVASTATIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84979895500     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.04.054     Document Type: Article

References (27)

1. 1 Sjouke, B., Kusters, D.M., Kindt, I., et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Hear J 36 (2014), 560–565.
2. 2 Hovingh, G.K., Davidson, M.H., Kastelein, J.J.P., O'Connor, A.M., Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 34 (2013), 962–971.
3. 3 Benn, M., Watts, G.F., Tybjærg-Hansen, A., Nordestgaard, B.G., Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 37 (2016), 1384–1394.
4. 4 Huijgen, R., Kindt, I., Defesche, J.C., Kastelein, J.J.P., Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J 33 (2012), 2325–2330.
5. 5 Smilde, T.J., van Wissen, S., Wollersheim, H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001), 577–581.
6. 6 Baigent, C., Keech, A., Kearney, P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
7. 7 Baigent, C., Blackwell, L., Emberson, J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
8. 8 van Herk-Sukel, M.P.P., van de Poll-Franse, L.V., Lemmens, V.E.P.P., et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 46 (2010), 395–404.
9. 9 RIVM. Classification of Medical Interventions version 2.6. 2005. Available at: http://class.who-fic.nl/browser.aspx?scheme=CMSV-nl.cla. Accessed June 30, 2015.
10. 10 World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. 1978, World Health Organization, Geneva, Switzerland Available at: http://apps.who.int/classifications/icd10/browse/2016/en Accessed September 18, 2015.
11. 11 Cole, S.R., Hernán, M.A., Adjusted survival curves with inverse probability weights. Comput. Methods Programs Biomed 75 (2004), 45–49.
12. 12 Xu, S., Ross, C., Raebel, M., Shetterly, S., Blanchette, C., Smith, D., Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13 (2010), 273–277.
13. 13 Pan, W., Akaike's information criterion in generalized estimating equations. Biometrics 57 (2001), 120–125.
14. 14 Harrel FE. The “Hmisc” Package, version 3.14-4. 2014. Available at: http://cran.r-project.org/web/packages/Hmisc/Hmisc.pdf. Accessed July 23, 2014.
15. 15 Stone, N.J., Robinson, J., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2889–2934.
16. 16 Versmissen, J., Oosterveer, D.M., Yazdanpanah, M., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
17. 17 Law, M.R., Wald, N.J., Thompson, S.G., By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ 308 (1994), 367–372.
18. 18 Grundy, S.M., Cleeman, J.I., Merz, C.N.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004), 720–732.
19. 19 Besseling, J., Kindt, I., Hof, M., Kastelein, J.J.P., Hutten, B.A., Hovingh, G.K., Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14, 000 mutation carriers. Atherosclerosis 233 (2014), 219–223.
20. 20 Benn, M., Watts, G.F., Tybjaerg-Hansen, A., Nordestgaard, B.G., Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 97 (2012), 3956–3964.
21. 21 Huijgen R, Versmissen J, Oosterveer DM, et al. Cascade screening for familial hypercholesterolemia: prevention of coronary artery disease in a large cohort of FH heterozygotes. In: Huijen R, editor. Familial Hypercholesterolemia: The Dutch Approach. Amsterdam, the Netherlands: 2012:288–304. Available at: http://dare.uva.nl/document/2/114977. Accessed August 20, 2015.
22. 22 Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 34 (2013), 3478–3490 a.
23. 23 Pijlman, A., Huijgen, R., Verhagen, S.N., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 209 (2010), 189–194.
24. 24 Marks, D., Wonderling, D., Thorogood, M., et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ, 324, 2002, 1303.
25. 25 Nherera, L., Marks, D., Minhas, R., et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 97 (2011), 1175–1181.
26. 26 Ridker, P.M., Danielson, E., Fonseca, F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008), 2195–2207.
27. 27 Cannon, C.P., Blazing, M., Giugliano, R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.